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Abstract 
 
Background: Apolipoprotein E (APOE), which its ε4 allele has been reported as a risk factor in late onset Alz-
heimer’s disease (AD), is the main cholesterol carrier in the brain. ATP-binding cassette transporter A1 (ABCA1) 
gene on chromosome 9, which has been known by genome-wide AD linkage study, has an important role in 
cellular cholesterol efflux. This study determines the association between sporadic AD and the human ABCA1 
and APOE gene polymorphisms in Iranian population. 
 
Methods: 154 AD cases and 162 control subjects from Iranian population were genotyped for APOE genotypes 
and ABCA1 polymorphism (R219K). 
 
Results: The frequency of ε2ε3 genotype was higher in control subjects comparing AD patients but was not 
significant (13% versus 5.8%) and ε3ε4 genotype frequency was significantly higher in AD cases comparing with 
control subjects. APOE-ε2 allele frequency in cases was lower than control subjects but this difference was not 
significant (4.5% versus 8%). Individuals carrying ε4 allele, developed AD 6.5 times more than non-carriers 
(OR=6.52, 95%CI=2.63-16.17). There was no significant association between ABCA1 polymorphism and AD.  
 
Conclusion: Unlike other studies, R219K polymorphism was not dependent on gender and APOE-ε4 allele and 
there was no association between APOE and ABCA1 in AD patients compared to controls. 
 
Keywords:  Alzheimer’s disease; Genetic association; Apolipoprotein E; Polymorphism; ATP-binding cassette 
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Introduction 
 
Alzheimer’s disease (AD), which presents progres-
sive cognitive defects such as memory loss, apraxia 
and personality changes, is the commonest cause of 
dementia in the mid and late ages.
1,2 Two neuropath-
ophysiological hallmarks of AD are intracellular neu-
rofibrillary tangles and beta amyloid plaques in brain 
blood vessels. As hundreds genes have been known 
as the risk factors for late onset AD, the well-known 
one is apolipoprotein E gene (APOE) which has been 
recognized as the most important risk factor in 65% 
of sporadic cases.
3 Apolipoprotein E is the main part 
of very low density lipoproteins, intermediate density 
lipoproteins (IDL), chylomicrons and the main cho-
lesterol carrier in the brain and its synthesis is inde-
pendent in central nervous system (CNS) and lung. 
As APOE expression is stimulated by any CNS dam-
ages or diseases, it seems that APOE regulates cho-
lesterol metabolism and distribution in the brain to 
repair and stabilize neurons’ membrane and myelin.
4-6 
Several lines of evidence show that cholesterol me-
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tabolism and Aβ deposition are related to each other. 
Cholesterol reducing drugs such as statin decrease 
brain Aβ level and increase non-amyloidogenic α-
secretase cleavage of amyloid precursor protein and 
lead in reduced Aβ deposition.
7-10 High cholesterol 
diet in transgenic animal models of AD leads in 
increased Aβ deposition in the brain.
8,11,12 On the 
other hand, it was shown that the prevalence of AD 
is 60%-70% lower in cholesterol reducing drug 
consumers.
1,13,14 Thus the risk of AD and Aβ depo-
sition can be altered by factors associated with cho-
lesterol level. 
The brain has the highest cholesterol content of 
the body (20%) and because of blood brain barrier, 
the cholesterol homeostasis is independent from cho-
lesterol level of plasma. Most of the brain cholesterol 
is immobilized in the myelin and the remaining is in 
neurons, glials and extracellular lipoproteins.
6 Every 
day, 6-7 mg of excess cholesterol is converted to 24 
S-hydroxycholesterol by 24 S-hydroxilase to 
transport out of the brain through blood brain barrier 
and the gene encoding 24 S-hydroxilase has found to 
be associated with the risk of AD.
15,16 Cellular choles-
terol is transported out of the cell by a mechanism 
called cholesterol efflux in which a membrane-
associated protein, ATP-binding cassette transporter 
A1 (ABCA1), transports the cholesterol to high den-
sity lipoproteins (HDL).
13 ABCA1 gene is located in 
9q31.3 position which has been shown to be linked 
with AD by previous studies.
17,18  Loss of ABCA1 
function causes Tangier’s disease which is character-
ized by absence of HDL, coronary artery disease and 
neuropathy. Like APOE, the expression of ABCA1 is 
regulated by RXR-LXR heterodimer and there are 
some evidences suggesting lack of APOE secretion 
from microglia, when ABCA1 is not expressed, so it 
seems that ABCA1 can influence APOE and choles-
terol metabolism in the CNS.
5,19 
In support for a link between AD and cholesterol 
metabolism, it has been supposed that ABCA1 poly-
morphisms may influence brain cholesterol homeo-
stasis and risk of developing AD. Association of 
ABCA1 polymorphisms and AD has been studied in 
different population and there are some positive and 
some negative results.
7,8,13,15,17,20,21  Raygani  et al. 
showed that APOE- ε4 allele was a risk factor in de-
veloping AD in Iranian population but the protective 
role for APOE- ε2 against AD in this population was 
not statistically significant.
22  This study determines 
the association between sporadic AD and the human 
ABCA1 and APOE gene polymorphisms in an Irani-
an population. 
 
Materials and Methods 
 
This case and control study involved 154 AD cases 
(mean age=78.55±7.80 years) and 162 control sub-
jects (mean age=77.14±6.95 years) in which AD cas-
es recruited using DSM IV criteria and control sub-
jects were included if they were older than 65 years 
old with no known neuropsychiatry disorders. The 
informed consent was signed by all of them or their 
legal guardians. The criterion for inclusion as a case 
was the diagnosis of AD diagnosed by the expert psy-
chiatrist and lacking any neurologic or psychiatric 
disorders for the control group. Subjects were exclud-
ed if they had any family history of dementia or neu-
rologic diseases. AD and control subjects were re-
cruited from Alzheimer’s society of Iran and Geriatric 
centers of Farzanegan, Mehrvarzan, Shayestegan, 
Kahrizak, Hasheminejhad and Rheumatism Center in 
Tehran, Iran from 2007 to 2008. The information re-
garding the age, sex, ethnicity, job and education 
were asked and recorded and finally 5 ml of peripher-
al blood sample was collected in tubes containing 200 
µl of 0.5 M EDTA. Genomic DNA was extracted 
from peripheral blood leukocytes using salting-out 
method. APOE was genotyped by PCR-RFLP method 
which had been described by Wenham et al.
23 DNA 
was amplified by polymerase chain reaction (PCR) 
using forward primer: 5´-TCC AAG GAG CTG CAG 
GCG GCG CA-3´; and Reverse primer: 5´-ACA 
GAA TCC GCC CCG GCC TGG TAC ACT GCC A-
3´. The 227 bp PCR products were digested by Hha I 
(10 U/µl, Fermentas) and loaded on a 12% poly-
acrylamide gel for electrophoresis; finally the gels 
were stained using silver staining method.  
To genotype ABCA1 in AD cases and control sub-
jects, a part of exon 7 of ABCA1 was amplified by 
polymerase chain reaction (PCR) using forward pri-
mer: 5´-CCT GTC ATT GTG CCT TGT G -3´; and 
reverse primer: 5´-GGA TTG GCT TCA GGA TGT 
C -3´. The 372 bp PCR product was digested by Sty I 
(10 U/µl, Fermentas) and loaded on an 8% poly-
acrylamide gel for electrophoresis; finally the gels 
were stained by silver staining method.  
APOE and ABCA1 alleles and genotypes fre-
quencies were analyzed through logistic regression, 
χ2 or Fisher’s Exact tests. Statistical significance 
was assumed when p value was less than 0.05. The 
statistical analysis and the odd ratios (OR) were de-Khorram Khorshid et al. 
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termined using SPSS software (versian13, Chicago, 
IL, USA) and free online epidemiological software 
of Open Epi (2.2.1).  
 
Results 
 
Distribution of age, sex, jobs, educational level and 
genetic background was almost the same in both 
groups, so there was no need to use any method for 
adjustment of cases and controls (Table 1). The mean 
age and number of females were slightly higher in 
patients compared to control subjects. Our data 
showed that the highest frequency of AD was ob-
served in housewives and the lowest was among 
farmers. People with academic education had the 
lowest frequency among patients and illiterate indi-
viduals had the most frequency. The samples were 
consisted of 5 Iranian genetic backgrounds in which 
Fars was the most common population.  
The frequencies of APOE genotypes and alleles in 
AD cases and control subjects were shown in Table 2. 
The frequency of ε2ε2 genotype in control subjects 
was lower than that in AD cases but it was not signif-
icant (p=0.444). The distribution of ε2ε3 genotype 
was not significantly different in both groups (13% in 
controls versus 5.8% in AD, p=0.128) and OR was 
found to be 0.53 (95%CI=0.23-1.21). The genotype 
frequency of ε3ε3 was higher in control subjects 
compared with patients (Reference Group). The ε3ε4 
genotype frequency in AD cases was significantly 
higher than that in control group (20.8% versus 3.7%, 
p=0.001).The distribution of ε2ε4 genotype was the 
same in both groups and different distribution of ε4ε4 
genotype in the groups was not significant (2% versus 0, 
Table 1: Comparison of mean age, sex, jobs, education levels and genetic backgrounds between AD cases and 
control subjects. 
Parameter  AD patients
(No.=154) 
Control subjects 
(No.=162) 
P value
Age   78.55±7.80
a 77.14±6.95  0.091 
Sex (M/F)
b   63/91  63/99  0.714 
 
Jobs 
Housewife 55.8%  56.2%  
 
0.938 
Own business  23.4%  21.0% 
Worker 9.2%  8.6% 
Farmer 3.2%  3.1% 
Employee 8.4%  11.1% 
     
 
Education 
levels 
Illiterate 41.6%  43.2%   
 
0.427 
Primary school  29.2%  29.6% 
Secondary school  16.2%  12.3% 
Diploma 11.1%  9.3% 
Academic 1.9%  5.6% 
     
Genetic back-
ground 
Fars 61.0%  63.6%   
 
0.490 
Turk 25.3%  25.3% 
Kurd 3.9%  1.8% 
Lor 0.7%  2.5% 
Gilak and Mazani  9.1%  6.8% 
a Mean±SD, 
b Male/Female 
 
Table 2: The genotype and allele frequencies were compared between AD cases and control subjects. 
Genotype/Allele Alzheimer 
No.=154 
Control
No.=162
P value Odds Ratio
Genotype  
ε3ε3 69.5%  82.1%  Rf 
a 
ε2ε2 1.3%  0.6%  0.444  2.48  (0.22-27.8) 
ε2ε3 5.8%  13%  0.128  0.53  (0.23-1.21) 
ε2ε4 0.6%  0.6%  0.439  1.24  (0.08-20.1) 
ε3ε4 20.8%  3.7%  0.001  6.52  (2.63-16.17) 
ε4ε4 2%  0  0.182  undefined 
Allele  
ε3 82.8%  90.1%  Rf 
a 
ε2 4.5%  8%  0.243  0.67  (0.34-1.32) 
ε4 12.7%  1.9%  0.001  7.44  (3.1-17.9) 
a Reference Group. 
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p=0.182). 
The APOE-ε4 allele frequency was significantly 
higher in AD cases compared with control subjects 
(12.7% versus 1.9%, p=0.001). Comparing allele fre-
quency in APOE- ε4 allele carriers with non-carriers, 
OR was found to be 6.52 (95%CI=2.63-16.17). The 
frequency of APOE-ε3 allele in patients was lower 
than that in control group (Reference Group). Despite 
of higher APOE-ε2 allele frequency in AD cases 
compared with control subjects, this difference was 
not statistically significant (p=0.243 and OR=0.67, 
95%CI=0.34-1.32) (Table 2).  
Table 3 shows APOE genotype and allele frequen-
cies distributed by sex groups. ε2ε3 genotype fre-
quency in control subjects was higher than AD sub-
jects in men and women group (p>0.05). The geno-
type frequency of ε3ε4 in AD cases was higher than 
control subjects in both male and female groups but it 
was significant just in female group (p=0.001). The 
frequency of APOE-ε4 allele in patients was signifi-
cantly higher than control subjects in both males and 
females with different OR [males: p=0.002, OR=8.3 
(1.86-37); females: p=0.001, OR=5.59 (2.07-15.05)]. 
The genotypes and alleles of ABCA1 gene was 
compared in two groups of AD cases and controls. As 
it has been summarized in Table 4, the GG genotype 
frequency was not different between AD cases and 
controls (Reference Group). Comparing GA and AA 
genotype frequencies, there was no significant differ-
ence between AD cases and control subjects (GA: 
p=0.451 and AA: p=0.696). No significant difference 
was observed between allele frequencies in cases and 
controls (p=0.592). Examining data stratified by gen-
der, neither female AD cases nor male AD cases 
showed significant genotype and allele frequencies 
compared with female and male controls.  
Furthermore, stratification of data by ε4 allele of 
APOE, which had been genotyped for the AD cases 
and control subjects in the previous study, did not 
change the results. ABCA1 genotypes and alleles of 
AD and control subjects were compared between ε4 
carriers and ε4 non-carriers (Table 5). Distribution of 
GG, GA and AA genotypes were not significantly 
different between AD cases and control subjects of ε4 
carriers and non-ε4 carriers. 
 
Discussion 
 
According to this study, APOE-ε4 allele is a risk   
factor for developing late onset AD in Iranian popula-
tion like many other populations.
24-29 Although ε2ε3 
genotype seems to play a protective role against AD 
but the protective role of APOE- ε2 allele has not  
Table 3: APOE genotype and allele frequencies distributed by sex.
Genotype/Allele Female Male
ApoE genotypes     
ε3/ε3 Rf
 a Rf
a 
ε2/ε3  P=0.522, OR=0.663 (0.22-1.75)  P=0.104, OR=0.23 (0.05-1.13) 
ε3/ε4  P=0.001, OR=7.86 (2.58-23.9)  P=0.080, OR=4.7 (0.96-22.8) 
ε4/ε4 No  data  P=0.319, OR= undefined 
APOE alleles     
ε3 Rf 
a Rf
a 
ε4  P=0.001, OR=5.59 (2.07-15.05)  P=0.002, OR=8.3 (1.86-37) 
ε2  P=0.157, OR=0.46 (0.17-1.19)  P=0.878, OR=0.8 (0.29-2.24) 
a Reference Group 
 
Table 4: Genotypes and allele frequencies in AD cases and control subjects by sex. 
 Total  Female Male 
 
Genotype 
AD 
(No.=154) 
Control 
(No.=162) 
P value AD 
(No.=91)
Control 
(No.=99)
P value AD 
(No.=63) 
Control 
(No.=63)
P value
GG 33.1%  37%  Rf
a 9.6% 39.4% Rf 23.8% 33.3% Rf
GA  48.7%  45.1%  0.451 0.4%  40.4% 0.803 55.6% 52.4% 0.341 
AA  18.2% 17.9% 0.696  16.4%  20.2%  0.487  0.6% 14.3%  0.197 
Allele        
G  57.5%  59.6%  0.592 59.6% 61.5% 0.699 51.6% 59.5% 0.205 
A 42.5%  40.4%  40.4%  38.5%  48.4%  40.5% 
a Reference Group Khorram Khorshid et al. 
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demonstrated in this study and it may be proved by a 
larger sample size. 
The risk of developing AD in individuals with 
ε2ε3 genotype is about 0.53 (95%CI=0.23-1.21) 
compared with individuals without this genotype so 
ε2ε3 genotype seems to be protective against AD 
whereas protective role of ε2 allele has not demon-
strated in Iranian population yet. APOE-ε4 allele car-
riers develops AD, 6.5 times more than non-carriers 
(6.52, 95%CI=2.63-16.17). This allele’s risk seems 
different in males and females. Different OR for ε4 
allele in men and women indicates that risk of AD in 
male APOE-ε4 allele carriers (OR=8.421, CI=1.894-
37.44) is higher than female carriers (OR=5.846, 
CI=2.173-15.73), so it seems that despite the age-
dependant and dosage-dependent manner of this al-
lele which were investigated in Iranian population by 
Raygani et al.,
22 it may act in a sex-dependent way as 
well. As three patients were observed with ε4ε4 geno-
type, it was not possible to assess the dosage-
dependent action of ε4 allele in this study.
 
As the study groups were similar based on poten-
tial confounders (age, sex, genetic background, job 
and education), it can be assumed that the results are 
mainly unbiased. There was no reliable history or ev-
idence for the time of AD onset, so we couldn't eval-
uate the effect of different genotypes or alleles on the 
age of onset in the AD subjects. In an autopsy-based 
study, the frequency of ε4 allele and ε4ε4, ε  3 ε4 geno-
types were 40%, 16.5% and 43.2% in AD patients 
and 16%, 2.2 and 20.9% in the control group.
30 In a 
group of African Americans AD patients, a signifi-
cantly increased risk of AD was associated with two 
ε4 alleles or one ε4 allele when compared to ε  3 ε3 
genotype.
31 In our study, the frequencies of ε4 allele 
and ε4ε4, ε3ε4 genotypes were lower than results of 
Raygani et al.,
22 but the proportion of them was the 
same and the results of two studies in Iranian popula-
tion are consistent. No significant association was 
found between ε2 allele or related genotypes and AD 
but it sounds to work as protective factor for AD; 
however this finding, should be confirmed in further 
studies with a larger sample size . 
In initial studies, it had been shown that ABCA1 
expression can affect the level of APOE expression. 
Increased amyloid deposition in ABCA1 null mice 
and position of this gene on chromosome 9, which 
was linked to AD, were another evidence to confirm 
ABCA1 gene as a target gene for AD association 
studies.
3,5 In 2003, Wollmer reported that A allele of 
ABCA1 causes 1.7 years delay at onset of AD and A 
allele carriers had 33% lower cholesterol in cerebro-
spinal fluid, than non-carriers of this allele.
15 Signif-
icant increased frequency of A allele in control sub-
jects compared with AD cases in Chinese population 
was reported by Wang et al. in 2007, while Sunder 
et al. reported that AD incidence is 1.5 times more 
frequent in A allele female carriers compared with 
female non-carriers in white American popula-
tion.
8,13 
In this study, ABCA1 and its association with AD 
was studied in Iranian population for the first time. 
No association was observed between genotypes and 
alleles of ABCA1and AD. In 2006, Shibata et al. re-
ported that ABCA1-A allele frequency was signifi-
cantly higher in APOE-ε4 carriers compared with ε4 
non-carriers.
7 Therefore it was decided to investigate 
about this finding, but stratification by gender and 
APOE-ε4 allele did not change the result and there 
was no association between genotypes and alleles of 
ABCA1 and the risk of AD among APOE-ε4 carriers 
and non-carriers. 
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Table 5: ABCA1 genotypes and alleles distribution in APOE ε4 carriers and APOE ε4 non-carriers. 
 APOE  ε4 carriers  APOE  ε4 non-carriers 
Genotype  
Frequency 
Controls 
(No.=7) 
Patients 
(No.=36) 
P value Controls 
(No.=155) 
Patients  
(No.=118) 
P value
GG 42.9%  25%  Rf
a 36.8% 35.6%  Rf 
GA 42.9%  58.3%  0.618
b 45.2%  45.8%  0.866 
AA 14.2%  16.7%  1
b 18%  18.6%  0.854 
Allele Frequency   
G 64.3%  54.2%  0.485  64.3% 54.2%  0.836  A 35.7%  45.8%  35.7%  45.8% 
a Reference Group, 
b Fischer exact test p value ABCA1 and APOE gene polymorphisms 
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